Search International and National Patent Collections

1. (WO2017202343) 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

Pub. No.:    WO/2017/202343    International Application No.:    PCT/CN2017/085765
Publication Date: Fri Dec 01 00:59:59 CET 2017 International Filing Date: Thu May 25 01:59:59 CEST 2017
IPC: C07D 487/04
A61K 31/5025
A61K 31/5377
A61K 31/541
Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
中国科学院上海药物研究所
Inventors: JIANG, Hualiang
蒋华良
LIU, Hong
柳红
GENG, Meiyu
耿美玉
ZHENG, Mingyue
郑明月
AI, Jing
艾菁
WANG, Yulan
王玉兰
WU, Xiaowei
吴小伟
LI, Shuangjie
李双杰
PENG, Xia
彭霞
LI, Chunpu
李淳朴
CHEN, Kaixian
陈凯先
WANG, Bao
王宝
Title: 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF
Abstract:
The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.